Actinogen Medical’s hopes—and stock price—have rebounded slightly from earlier this month, when the Australian biotech announced its cortisol blocker had failed to improve attention and memory in ...
Vivoryon Therapeutics’ glutaminyl cyclase inhibitor has failed a second phase 2 Alzheimer’s disease study this year, leaving the German biotech trying to find a silver lining in the drug’s potential ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results